418 related articles for article (PubMed ID: 10069406)
1. Limiting neurological damage after stroke: a review of pharmacological treatment options.
Read SJ; Hirano T; Davis SM; Donnan GA
Drugs Aging; 1999 Jan; 14(1):11-39. PubMed ID: 10069406
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in cerebrovascular disease.
Jain KK
Expert Opin Investig Drugs; 2000 Apr; 9(4):695-711. PubMed ID: 11060703
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with neuroprotectants and thrombolytics in acute ischaemic stroke.
Steiner T; Hacke W
Eur Neurol; 1998 Jul; 40(1):1-8. PubMed ID: 9693224
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective therapies in stroke.
Zivin JA
Drugs; 1997; 54 Suppl 3():83-8; discussion 88-9. PubMed ID: 9360855
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection in cerebral ischaemia: facts and fancies--the need for new approaches.
Wahlgren NG; Ahmed N
Cerebrovasc Dis; 2004; 17 Suppl 1():153-66. PubMed ID: 14694293
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly.
Green AR
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S325-38. PubMed ID: 18059324
[TBL] [Abstract][Full Text] [Related]
7. Trends and future developments in the pharmacological treatment of acute ischaemic stroke.
del Zoppo GJ; Wagner S; Tagaya M
Drugs; 1997 Jul; 54(1):9-38. PubMed ID: 9211077
[TBL] [Abstract][Full Text] [Related]
8. Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
Prescrire Int; 2005 Aug; 14(78):146-52. PubMed ID: 16106599
[TBL] [Abstract][Full Text] [Related]
9. [Vinpocetin in neurological diseases].
Szapáry L; Késmárky G; Tóth K; Misnyovszky M; Tóth T; Balogh A; Nagy K; Németh GY; Fehér G
Ideggyogy Sz; 2012 Nov; 65(11-12):387-93. PubMed ID: 23289173
[TBL] [Abstract][Full Text] [Related]
10. [Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone].
Levi M
Ned Tijdschr Geneeskd; 2008 Feb; 152(8):423-5. PubMed ID: 18361189
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection in acute ischaemic stroke. Current status and future potential.
Lutsep HL; Clark WM
Drugs R D; 1999 Jan; 1(1):3-8. PubMed ID: 10565968
[TBL] [Abstract][Full Text] [Related]
12. AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs?
Weiser T
Curr Pharm Des; 2002; 8(10):941-51. PubMed ID: 11945140
[TBL] [Abstract][Full Text] [Related]
13. Hypothermia for acute ischaemic stroke.
Wu TC; Grotta JC
Lancet Neurol; 2013 Mar; 12(3):275-84. PubMed ID: 23415567
[TBL] [Abstract][Full Text] [Related]
14. Evolving therapeutic approaches to treating acute ischemic stroke.
Weinberger JM
J Neurol Sci; 2006 Nov; 249(2):101-9. PubMed ID: 17005205
[TBL] [Abstract][Full Text] [Related]
15. The use of antithrombotic drugs in artery disease.
Gallus AS
Clin Haematol; 1986 May; 15(2):509-59. PubMed ID: 3524934
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic drugs and ischaemic stroke.
Prescrire Int; 2013 Nov; 22(143):270-1. PubMed ID: 24427842
[TBL] [Abstract][Full Text] [Related]
17. Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research.
Reis C; Akyol O; Ho WM; Araujo C; Huang L; Applegate R; Zhang JH
Biomed Res Int; 2017; 2017():4863079. PubMed ID: 28286764
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
Lang W; Stadler CH; Poljakovic Z; Fleet D;
Int J Stroke; 2013 Feb; 8(2):95-104. PubMed ID: 23009193
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke.
Karsy M; Brock A; Guan J; Taussky P; Kalani MY; Park MS
Neurosurg Focus; 2017 Apr; 42(4):E3. PubMed ID: 28366066
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection as initial therapy in acute stroke. Third Report of an Ad Hoc Consensus Group Meeting. The European Ad Hoc Consensus Group.
Cerebrovasc Dis; 1998; 8(1):59-72. PubMed ID: 9645985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
